GAfPA Statement on United States-Mexico-Canada Agreement

Patients who are eager for the next generation of treatments and cures will be well served by the United States-Mexico-Canada Agreement.  This agreement provides intellectual property protections that promote patient access to innovative medicine, clearing the way for new treatments for cancer, Alzheimer’s, diabetes and many other conditions.

Sign up to receive updates from GAfPA